Nemus Bioscience Adds to Senior Leadership Team LONG BEACH, CA, May 07, 2018 (GLOBE NEWSWIRE) -- Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially...

Nemus Secures Emerald Health as Strategic Majority Investor to help Advance Clinical Development of Novel Cannabinoid-based Therapeutics Nemus Bioscience Receives $400,000 Funding under Convertible Bridge Loan and Closes Initial $1,500,000 Private Placement COSTA MESA, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- NEMUS Bioscience, Inc....

Nemus Bioscience Announces Closing of Convertible Bridge Loan and Anticipated Equity Financing COSTA MESA, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) -- NEMUS Bioscience, Inc. (OTCQB: NMUS, “Nemus”) today announced that it entered into agreements with Emerald Health Sciences Inc. (“Emerald”),...

NEMUS Bioscience, Inc. Retains MZ Group as Investor Relations Advisor COSTA MESA, Calif., March 24, 2015 (GLOBE NEWSWIRE) -- NEMUS Bioscience Inc. (OTCQB: NMUS), a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities...

NEMUS Bioscience, Inc. initiates anti-infective program with focus on MRSA COSTA MESA, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- NEMUS Bioscience, Inc. (OTCQB: NMUS) announced today that the company would begin studies concerning the medical utility of cannabinoids as...